Effects of dapagliflozin on kidney function (glomerular filtration rate) in subjects with type 2 diabetes

Study identifier:MB102-035

ClinicalTrials.gov identifier:NCT00976495

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

Dapagliflozin, Placebo, Hydrochlorothiazide

Sex

All

Actual enrollment

154

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Oct 2009
Primary Completion Date: 01 Nov 2010
Study Completion Date: 01 Nov 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2017 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Astra-Zeneca, Bristol-Myers Squibb

Inclusion and exclusion criteria